FIELD: medicine; oncology.
SUBSTANCE: in treatment of breast cancer in mammal introduction of rapamicine esters with aromatase inhibitor in form of combination o in pharmaceutical composition is realised. As rapamicine esters CCI-779 or 42-O-(2-hdroxy)ethylrapamicine is introduced, as aromatase inhibitor - letrozole in subtherapeutic doses.
EFFECT: enhancing anti-tumor effect due to synergetic effect resulting from combination of definite rapamicine ester with particular aromatase inhibitor.
7 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CCI-779 FOR AMPHICYTE LYMPHOMA TREATMENT | 2004 |
|
RU2358731C2 |
| ANTITUMOUR COMBINATIONS WITH MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2012 |
|
RU2632104C2 |
| ANTI-TUMOUR COMBINATIONS MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2006 |
|
RU2451524C2 |
| LYOPHILISED COMPOSITIONS CCI-779 | 2004 |
|
RU2345772C2 |
| RAPAMYCINE HYDROXY ETHERS-CONTAINING PARENTERAL COMPOSITIONS | 2003 |
|
RU2344821C2 |
| ANTICANCER ACTIVITY OF CCI-779 IN PAPILLARY RENAL CELL CARCINOMA | 2008 |
|
RU2501559C2 |
| COMBINATION AND METHOD FOR PROPHYLAXIS OF BREAST CANCER | 2002 |
|
RU2322981C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2665138C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2659725C2 |
| INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
